This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
the Emil Fischer Medal of the Society of German Chemists (1922), the Cannizaro Prize of the Royal Academy of Science in Rome (1938), the Copernicus Prize of the University of Konigsberg (1941), the Gothenius Medal of the Akademie der Naturforscher (1943), the Max Planck Medal of the German Physical Society, with Lise Meitner (1949), the Goethe Medal of the city of Frankfurt-on-the-Main (1949), the Golden Paracelsus Medal of the Swiss Chemical Society (1953), the Faraday Lectureship Prize with Medal from the Royal Society of Chemistry (1956), the Grotius Medal of the Hugo Grotius Foundation (1956), the Wilhelm Exner Medal of the Austrian Industry Association (1958), the Helmholtz Medal of the Berlin-Brandenburg Academy of Sciences and Humanities (1959), and the Harnack medal in Gold from the Max Planck Society (1959).
The principles outlined by Magati in his De rara medicatione vulnerum excited a great deal of debate: they were confirmed by the renowned physician Ludovico Settala (1552–1633) but were challenged mostly by Daniel Sennert.
Diisopropylfluorophosphate (DFP) is an example of an irreversible protease inhibitor (see the "DFP reaction" diagram). The enzyme hydrolyses the phosphorus–fluorine bond, but the phosphate residue remains bound to the serine in the active site, deactivating it. Similarly, DFP also reacts with the active site of acetylcholine esterase in the synapses of neurons, and consequently is a potent neurotoxin, with a lethal dose of less than 100 mg. Suicide inhibition is an unusual type of irreversible inhibition where the enzyme converts the inhibitor into a reactive form in its active site. An example is the inhibitor of polyamine biosynthesis, α-difluoromethylornithine (DFMO), which is an analogue of the amino acid ornithine, and is used to treat African trypanosomiasis (sleeping sickness). Ornithine decarboxylase can catalyse the decarboxylation of DFMO instead of ornithine (see the "DFMO inhibitor mechanism" diagram). However, this decarboxylation reaction is followed by the elimination of a fluorine atom, which converts this catalytic intermediate into a conjugated imine, a highly electrophilic species. This reactive form of DFMO then reacts with either a cysteine or lysine residue in the active site to irreversibly inactivate the enzyme. Since irreversible inhibition often involves the initial formation of a non-covalent enzyme inhibitor (EI) complex, it is sometimes possible for an inhibitor to bind to an enzyme in more than one way.
Compared to the City of Toronto as a whole, industry in the district is similar in all labour force categories, save for manufacturing which is higher in the district, and professional, scientific and technical services which are lower. Notable companies that have their headquarters in the district include Toyota Canada, Owens Corning (Toronto), Elizabeth Grant International, Enterprise Holdings, Inc., Thomson Carswell, Bell Media, Teva Canada, Cinram, Royal Doulton, SKF, Amphenol, Dart Canada, Mastermind Toys, Alfa Laval, President's Choice Financial, Aviva, Yellow Pages Group, Telus, and Lee Kum Kee Canada. The pizza chains 241 Pizza and Pizza Nova have their headquarters in Scarborough. Amazon opened a new fulfillment centre in north Scarborough in 2020. Large companies that have moved out of Scarborough include: General Motors Canada Van Assembly plant (1993) and Eli Lilly Canada (2019). A high-density business district has been built up in Scarborough City Centre. Points of interest in the area include Scarborough Town Centre, Albert Campbell Square, Street Eats Market, many surrounding stores, and government and business offices. The area has become one of Toronto's secondary business districts outside of Downtown Toronto.
April 21, 1944: Women are granted the right to vote and to stand for election, by ordinance of the Provisional Government of the French Republic then located in Algiers. April 12, 1945: Ordinance on divorce and legal separation. April 29, 1945: First vote with women participating as voters, during municipal elections. September 1, 1945: Ordinance on paternal correction, notably abolishing the "right to paternal correction." October 4, 1945: Ordinance establishing Social Security; its provisions include the creation of mandatory maternity leave (14 weeks) with compensation amounting to half of the salary. October 9, 1945: Creation of the National School of Administration (ENA), which accepts women, provided they do not seek positions strictly reserved for men. October 19, 1945: Ordinance establishing the French Nationality Code. November 2, 1945: Ordinance on maternal and child protection. April 11, 1946: Law allowing women to access the judiciary. April 13, 1946: Ban on brothels and strengthening the fight against pimping, by the so-called "Marthe Richard law." April 24, 1946: Law establishing a sanitary and social registry of prostitution. May 18, 1946: Law granting an additional leave to heads of household, whether salaried, civil servants, or public service agents, for each birth in their household. July 30, 1946: Order repealing provisions allowing wage reductions for "female wages." August 22, 1946: Law establishing the family benefits system.
Sources: en.wikipedia.org
== Skin contracture == Wound contraction, where the edges of the skin are pulled together to close the wound, is a normal part of wound healing. However, large wounds and abnormal wound healing cause skin contractures by excessively tightening the skin and limiting movement. A skin contracture due to a burn is known as a burn scar contracture. Large areas of missing skin (such as large burns, grazes, and gouges) drastically reduce the area of skin causing it to become tight when pulled together during wound healing. Scars initially lack elasticity with synthesis of elastic tissue fibres (elastogenesis) being a function of duration and site of the scar. Deep wounds and abnormal wound healing causes abnormal scarring such as hypertrophic scars. Studies on hypertrophic scars have shown a lack of improvement to both elasticity and stiffness suggesting a prolonged healing phase without amelioration seen in a normal wound-healing curve. Surgery can help alleviate skin contractures in the form of skin grafts and removal of hypertrophic scars. For hypertrophic scars, timing is important when considering surgery, as over time scars will mature and may show decreased contractures along with flattening, softening, and repigmentation without surgical intervention.
==== Lithium ==== Lithium has been used to augment antidepressant therapy in those who have failed to respond to antidepressants alone. As an augmentation agent for major depression, lithium is much more effective than placebo. Lithium augmentation has proven efficacy in treating major depressive disorder in multiple randomized controlled trials. For treatment-resistant depression, lithium augmentation reduces the odds of remaining ill by 56-95%. In the STAR-D study, for patients who had not achieved remission with two previous treatment trials, an additional 15.9% achieved remission. A disadvantage of lithium versus other augmentation agents is the need for occasional blood tests to monitor lithium levels. Lithium dramatically decreases the suicide risk in recurrent major depression by 88.5%. In addition to its effects on suicide, lithium also decreases mortality from all causes in people with mood disorders.
== History == Turquoise was mined by pre-Columbian Native Americans in deposits in New Mexico (Los Cerrillos) and likely in California as well. Additionally, it was used by the Ancient Egyptians, although not very commonly. Several turquoise artefacts, such as beads and reclining calves, have also been found in Greece, dating to the Mycenaean era (1500BC). Turquoise mining later attracted brief European interest in the late 1800s. Prices peaked in 1890, then collapsed by 1912, ending large-scale operations. During Mohammad Khodabanda reign (1578–1587), accumulated turquoise dust from fifty years of mining in Safavid Iran was squandered lavishly, reflecting royal excess amid economic hardship, political discord, and rising factionalism among the qezelbash elite.
== Origin of eukaryotes == The great oxygenation event began with the biologically induced appearance of oxygen in the Earth's atmosphere about 2.45 billion years ago. The rise of oxygen levels due to cyanobacterial photosynthesis in ancient microenvironments was probably highly toxic to the surrounding biota. Under these conditions, the selective pressure of oxidative stress is thought to have driven the evolutionary transformation of an archaeal lineage into the first eukaryotes. Oxidative stress might have acted in synergy with other environmental stresses (such as ultraviolet radiation and/or desiccation) to drive this selection. Selective pressure for efficient repair of oxidative DNA damages may have promoted the evolution of eukaryotic sex involving such features as cell-cell fusions, cytoskeleton-mediated chromosome movements and emergence of the nuclear membrane. Thus, the evolution of meiotic sex and eukaryogenesis may have been inseparable processes that evolved in large part to facilitate repair of oxidative DNA damages.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.